Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks A Significant Shift In Chronic Obstructive Pulmonary Disease ...
(MENAFN- PR Newswire) After over a decade without notable progress in treating chronic obstructive pulmonary disease, patients with this ongoing condition now have two new treatment options, with more expected in the future. Regeneron and Sanofi recently …